Q-omics provides the consensus-scored SEMA5A profile across patient tissues and cancer cell-line models. SEMA5A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SEMA5A is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, SEMA5A RNA expression shows 18,693 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where SEMA5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEMA5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEMA5A survival associations across molecular data types. SEMA5A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEMA5A RNA expression–survival associations across cancer types. High SEMA5A expression shows unfavorable associations in STAD and LGG, but favorable associations in KIRC, HNSC, KIRP and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SEMA5A RNA expression.
This table summarizes SEMA5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SEMA5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEMA5A shows lower tumor expression in LUAD, KICH, COAD, LUSC and BRCA and higher tumor expression in STAD. The LUAD box plot shows higher SEMA5A RNA expression in normal versus tumor tissue (log2 FC = −2.461, t-test p < 0.001).
This table shows molecular features associated with SEMA5A in patient tissues and cancer cell lines. In patient samples, SEMA5A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEMA5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
